FDA Approves Merck's Welireg and Eisai's Lenvima Combination for Advanced Kidney Cancer
The U.S. Food and Drug Administration (FDA) has approved a combination therapy of Merck & Co.'s Welireg (belzutifan) and Eisai Inc.'s Lenvima (lenvatinib) as second-line treatment for patients with advanced renal cell carcinoma featuring clear cells. This approval follows positive results from the open-label, randomized clinical trial known as LITESPARK-011. The regimen is intended to provide an additional therapeutic option after initial treatments have failed or ceased to be effective in managing this form of kidney cancer. The decision by the FDA reflects a growing focus on targeted therapies for specific subtypes of renal cell carcinoma, which represents one of the most common forms of kidney cancer globally.
